...
首页> 外文期刊>The Journal of Endocrinology: The Journal of the Society for Endocrinology >Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells
【24h】

Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells

机译:糖皮质激素受体介导的细胞凋亡:癌细胞耐药机制

获取原文

摘要

Glucocorticoids (Gcs) are commonly used to treat patients suffering from a wide range of cancers. Their main therapeutic role is based on Gc receptor (GR)-mediated mechanisms that trigger cell death but this varies depending on the cancer type. This review aims to provide an overview of the mechanisms of Gc-induced cell death and more importantly the changes in GR that lead to resistance to Gc treatment in cancer. The three main cancer types, which are susceptible to Gc resistance and therefore loss of Gc-induced apoptotic effects, are acute lymphoblastic leukaemia, osteosarcoma and small-cell lung carcinoma. A common theme is the loss of GR function and/or a downregulation of GR expression which leads to failure of the cell death-inducing effects of Gcs. Loss of GR function is attributed to mutations in the GR gene, and in some cases a dominant-negative effect on any functional GR still present. The downregulation of GR expression can be due to decreased GR promoter activation, increased GR promoter methylation or increased expression of alternative splice isoforms of GR that have decreased transcriptional activity. Understanding the mechanisms behind Gc-triggered apoptosis and the resistance to it in these cancer types will help in further refining treatment regimens for patients and will decrease the chance of relapse caused by Gc-resistant cancer phenotypes.
机译:糖皮质激素(Gcs)通常用于治疗患有多种癌症的患者。它们的主要治疗作用基于触发细胞死亡的Gc受体(GR)介导的机制,但这取决于癌症类型而有所不同。这篇综述旨在概述Gc诱导的细胞死亡的机制,更重要的是,GR的变化导致对癌症中的Gc治疗产生抗药性。易受Gc耐药并因此丧失Gc诱导的凋亡作用的三种主要癌症类型是急性淋巴细胞白血病,骨肉瘤和小细胞肺癌。一个共同的主题是GR功能的丧失和/或GR表达的下调,这导致了Gcs的细胞死亡诱导作用的失败。 GR功能的丧失归因于GR基因中的突变,并且在某些情况下,对仍然存在的任何功能性GR起显性负作用。 GR表达的下调可能是由于GR启动子激活降低,GR启动子甲基化增强或转录活性降低的GR替代剪接异构体表达增加所致。了解Gc触发的细胞凋亡背后的机制及其在这些癌症类型中的抵抗力将有助于进一步细化患者的治疗方案,并减少由Gc耐药的癌症表型引起的复发机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号